Comparison of Adjuvant Efficacy of Chitosan and Aluminum Hydroxide for Intraperitoneally Administered Inactivated Influenza H5N1 Vaccine

被引:20
作者
Chang, Haiyan [2 ]
Li, Xiaoman [2 ]
Teng, Yong [2 ]
Liang, Yan [2 ]
Peng, Bo [2 ]
Fang, Fang [2 ]
Chen, Ze [1 ,2 ,3 ]
机构
[1] Shanghai Inst Biol Prod, Shanghai 200052, Peoples R China
[2] Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China
[3] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
AVIAN INFLUENZA; A H5N1; ANTIBODY-RESPONSES; VIRUS-VACCINE; IMMUNOGENICITY; THREAT; TRANSMISSION; DERIVATIVES; PROTECTION; SAFETY;
D O I
10.1089/dna.2009.0977
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A safe and effective adjuvant is important to develop vaccines against highly pathogenic avian influenza virus. Chitosan, a derivative from the natural amino polysaccharide chitin, has been proved to be an effective adjuvant for inactivated influenza virus vaccine. In this study, protective immunity in mice provided by chitosan-adjuvanted inactivated H5N1 vaccine was compared with that from an aluminum hydroxide-adjuvanted one. Mice were injected intraperitoneally once or twice with various dosages of inactivated vaccine alone or in combination with an adjuvant (chitosan or aluminum hydroxide). To test the immunization effect, mice were challenged with a lethal dose of H5N1 virus. The results showed that the adjuvanted vaccines were more effective than adjuvant-free ones in inducing humoral immune responses and protecting mice against lethal challenge. Chitosan was comparable to the alum adjuvant in efficacy. These findings indicated that chitosan might be a candidate adjuvant for parenteral administration of inactivated influenza vaccines.
引用
收藏
页码:563 / 568
页数:6
相关论文
共 40 条
  • [21] Aluminium compounds for use in vaccines
    Lindblad, EB
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (05) : 497 - 505
  • [22] A mucosal vaccine against diphtheria:: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery
    McNeela, EA
    O'Connor, D
    Jabbal-Gill, I
    Illum, L
    Davis, SS
    Pizza, M
    Peppoloni, S
    Rappuoli, R
    Mills, KHG
    [J]. VACCINE, 2000, 19 (9-10) : 1188 - 1198
  • [23] Revisiting Freund's incomplete adjuvant for vaccines in the developing world
    Miller, LH
    Saul, A
    Mahanty, S
    [J]. TRENDS IN PARASITOLOGY, 2005, 21 (09) : 412 - 414
  • [24] NISHIMURA K, 1990, Molecular Biotherapy, V2, P115
  • [25] ADJUVANT ACTIVITY OF CHITIN DERIVATIVES IN MICE AND GUINEA-PIGS
    NISHIMURA, K
    NISHIMURA, S
    NISHI, N
    NUMATA, F
    TONE, Y
    TOKURA, S
    AZUMA, I
    [J]. VACCINE, 1985, 3 (05) : 379 - 384
  • [26] Nishimura K, 1984, Vaccine, V2, P93, DOI 10.1016/S0264-410X(98)90039-1
  • [27] Normile D, 2006, SCIENCE, V312, P1855
  • [28] CHITOSAN-MEDIATED STIMULATION OF MACROPHAGE FUNCTION
    PELUSO, G
    PETILLO, O
    RANIERI, M
    SANTIN, M
    AMBROSIO, L
    CALABRO, D
    AVALLONE, B
    BALSAMO, G
    [J]. BIOMATERIALS, 1994, 15 (15) : 1215 - 1220
  • [29] Vaccine adjuvants: Current state and future trends
    Petrovsky, N
    Aguilar, JC
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (05) : 488 - 496
  • [30] Effective nasal influenza vaccine delivery using chitosan
    Read, RC
    Naylor, SC
    Potter, CW
    Bond, J
    Jabbal-Gill, I
    Fisher, A
    Illum, L
    Jennings, R
    [J]. VACCINE, 2005, 23 (35) : 4367 - 4374